Sillajen Biotherapeutics (215600):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Sillajen Biotherapeutics (215600) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8279
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:24
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:韓国
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Sillajen Biotherapeutics (SillaJen), formerly SillaJen Inc, is a biotechnology company that designs and develops oncolytic immunotherapeutics for the treatment of cancer. The company’s pipeline products comprise Pexa-Vec, an oncolytic immunotherapeutic virus which is in Phase III trial that is used for the treatment of primary liver cancer. It also develops JX929, a chemosensitizing oncolytic immunotherapy that eradicates cancer; activates chemotherapy in cancer tissue; administers as a monotherapy to patients with breast, colorectal, and pancreatic cancer; and treats melanoma and metastatic colon cancer. The company operates in South Korea and the US. Sillajen is headquartered in Busan, South Korea.

Sillajen Biotherapeutics (215600) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Sillajen Biotherapeutics, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Sillajen Biotherapeutics, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Sillajen Biotherapeutics, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Sillajen Biotherapeutics, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Sillajen Biotherapeutics, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Sillajen Biotherapeutics, Pharmaceuticals & Healthcare, Deal Details 10
Private Equity 10
Medivate Partners Invests in SillaJen 10
Partnerships 11
SillaJen Enters into R&D Agreement with National Cancer Institute 11
Regeneron Pharma and SillaJen Biotherapeutics Enter into Agreement 12
Transgene Amends Agreement With SillaJen 13
Equity Offering 14
SillaJen Plans to Raise Funds in IPO 14
Debt Offering 15
SillaJen Plans to Raise up to USD42 Million in Private Placement of Bonds 15
Acquisition 16
SillaJen Completes Acquisition Of Jennerex For US$150 Million 16
SillaJen Acquires Hibiscus Biotherapeutics 18
Sillajen Biotherapeutics – Key Competitors 19
Sillajen Biotherapeutics – Key Employees 20
Sillajen Biotherapeutics – Locations And Subsidiaries 21
Head Office 21
Other Locations & Subsidiaries 21
Recent Developments 22
Product News 22
04/12/2017: Transgene and Institut Bergonie Start the Phase 2 Part of the METROmaJX Trial 22
Clinical Trials 23
Apr 24, 2017: SillaJen And Transgene Announce the Enrollment of the First European Patient in Multinational Phase 3 Trial For Pexa-Vec in Advanced Liver Cancer 23
Appendix 24
Methodology 24
About GlobalData 24
Contact Us 24
Disclaimer 24

List of Tables
Sillajen Biotherapeutics, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Sillajen Biotherapeutics, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Sillajen Biotherapeutics, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Sillajen Biotherapeutics, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Sillajen Biotherapeutics, Deals By Therapy Area, 2012 to YTD 2018 8
Sillajen Biotherapeutics, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Medivate Partners Invests in SillaJen 10
SillaJen Enters into R&D Agreement with National Cancer Institute 11
Regeneron Pharma and SillaJen Biotherapeutics Enter into Agreement 12
Transgene Amends Agreement With SillaJen 13
SillaJen Plans to Raise Funds in IPO 14
SillaJen Plans to Raise up to USD42 Million in Private Placement of Bonds 15
SillaJen Completes Acquisition Of Jennerex For US$150 Million 16
SillaJen Acquires Hibiscus Biotherapeutics 18
Sillajen Biotherapeutics, Key Competitors 19
Sillajen Biotherapeutics, Key Employees 20
Sillajen Biotherapeutics, Other Locations 21
Sillajen Biotherapeutics, Subsidiaries 21

List of Figures
Sillajen Biotherapeutics, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Sillajen Biotherapeutics, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Sillajen Biotherapeutics, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Sillajen Biotherapeutics, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Sillajen Biotherapeutics, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Sillajen Biotherapeutics, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Sillajen Biotherapeutics, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Sillajen Biotherapeutics, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Sillajen Biotherapeutics (215600):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Power Assets Holdings Limited
    Power Assets Holdings Limited - Strategy, SWOT and Corporate Finance Report Summary Power Assets Holdings Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Leonardo UK Ltd:企業の戦略・SWOT・財務情報
    Leonardo UK Ltd - Strategy, SWOT and Corporate Finance Report Summary Leonardo UK Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • ITT Inc (ITT):企業の財務・戦略的SWOT分析
    ITT Inc (ITT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the pot …
  • Tredegar Corp (TG):企業の財務・戦略的SWOT分析
    Tredegar Corp (TG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • IBIDEN Co Ltd (4062):企業の財務・戦略的SWOT分析
    IBIDEN Co Ltd (4062) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Service Corporation International (SCI):企業の財務・戦略的SWOT分析
    Service Corporation International (SCI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • CCP Technologies Ltd (AGX)-製薬・医療分野:企業M&A・提携分析
    Summary CCP Technologies Ltd (CCP), formerly Agenix Ltd is a biotechnology company that offers molecule drugs. The company develops small molecule drugs and monoclonal antibody-based diagnostics for the treatment of various diseases. It develops DiagnostIQ rapid point-of-care human diagnostic techno …
  • Living Cell Technologies Ltd (LCT):製薬・医療:M&Aディール及び事業提携情報
    Summary Living Cell Technologies Ltd (LCT) is a biotechnology company that develops cell-based therapeutics for the treatment of neurological diseases, diabetes, and stroke and hearing loss. It focuses on discovering regenerative treatments which restore function using naturally occurring cells. LCT …
  • Layne Christensen Co (LAYN):石油・ガス:M&Aディール及び事業提携情報
    Summary Layne Christensen Company (Layne) is a water management, construction and drilling company. It provides solutions to essential natural resources such as water, mineral and energy. The company’s service portfolio includes hydrological studies, site selection, well design, drilling, well rehab …
  • Aster DM Healthcare-製薬・医療分野:企業M&A・提携分析
    Summary Aster DM Healthcare (Aster DM), formerly Dr Moopens Healthcare Management Services LLC is a healthcare service provider that provides patient care services. The company offers services such as cardiac surgery, mobile medical units, village adoption, early cancer detection centers and dialysi …
  • Blue Nile, Inc.:企業の戦略・SWOT・財務情報
    Blue Nile, Inc. - Strategy, SWOT and Corporate Finance Report Summary Blue Nile, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • California Water Service Group (CWT):企業の財務・戦略的SWOT分析
    Summary California Water Service Group (California Water Service) is a utility service provider that offers wastewater services and water operation and maintenance services. The utility provides services such as water and wastewater utility services, and operating water and wastewater systems servic …
  • Compumedics Ltd (CMP):企業の財務・戦略的SWOT分析
    Summary Compumedics Ltd (Compumedics) is a medical device company that develops and commercializes computer-based medical products. The company designs, develops and commercializes computer aided medical diagnostic systems. It provides product categories such as sleep diagnostics, neurology diagnost …
  • Celulose Nipo-Brasileira SA:企業の戦略的SWOT分析
    Celulose Nipo-Brasileira SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major product …
  • Great Portland Estates Plc (GPOR):企業の財務・戦略的SWOT分析
    Great Portland Estates Plc (GPOR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • Nielsen Holdings plc (NLSN):企業の財務・戦略的SWOT分析
    Nielsen Holdings plc (NLSN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Chesapeake Utilities Corp (CPK):企業の財務・戦略的SWOT分析
    Summary Chesapeake Utilities Corp (Chesapeake), a subsidiary of Chesapeake Energy Corp is a utility service provider that markets and distributes natural gas. The utility transmits, distributes, and markets propane, electricity, and natural gas. It also provides online bill payment, energy conservat …
  • Aurinia Pharmaceuticals Inc (AUP):製薬・医療:M&Aディール及び事業提携情報
    Summary Aurinia Pharmaceuticals Inc (Aurinia Pharmaceuticals), formerly Isotechnika Pharma Inc, is a clinical stage biopharmaceutical company which develops and commercializes therapies for the treatment of debilitating diseases. Voclosporin, the company’s product candidate under clinical developmen …
  • Sichuan Kelun Pharmaceutical Co Ltd (002422):製薬・医療:M&Aディール及び事業提携情報
    Summary Sichuan Kelun Pharmaceutical Co., Ltd. (Kelun) is engaged in manufacturing and distribution of IV Solutions. The company’s products portfolio includes glucose injection, sodium chloride injection, glucose and sodium chloride injection, ringer’s injection, lactated ringer’s injection, compoun …
  • PFM Packaging Machinery S.p.a.:企業の戦略・SWOT・財務情報
    PFM Packaging Machinery S.p.a. - Strategy, SWOT and Corporate Finance Report Summary PFM Packaging Machinery S.p.a. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆